We’re Changing the Cardiology Experience
Because You Deserve Better Care.
The practice of medicine, especially preventive cardiology, is failing patients because it focuses on general guidelines based mostly on numbers: “What’s your LDL?”, “What’s your BMI?” And that’s usually where it stops. It’s dangerous because it focuses on an equation instead of the individual. You are not your numbers. Your body is unique and deserves to be treated as such. We need a transformative shift in cardiology and preventive health care that considers you as an individual.
Let’s Talk
Send us a message and let us know how we can help you.
Introducing
Concierge Preventive Cardiology
with Dr. Scher
What if you could combine…
Now with Dr. Scher’s Concierge Preventative Cardiology, you can!
WELCOME TO
BOUNDLESS HEALTH WITH DR. SCHER
a revolutionary approach to optimizing your health and life!
Find out if this works for you
Connect with Dr. Scher today to see if this model is right for you.
Let’s Talk
Send us a message and let us know how we can help you.
Meet Dr. Scher, MD
CREATOR OF CONCIERGE PREVENTIVE CARDIOLOGY

Hi, I’m Dr. Bret Scher, and I’m changing the direction of preventive cardiology to better you with the care you deserve. I’m also the CEO and Lead Physician at Boundless Health and the Low Carb Cardiologist. I spent the past 15 years as a frustrated cardiologist. My patients weren’t achieving their optimal health, and I didn’t have the time or resources to guide them. That’s why I am revolutionizing my practice of medicine, and why I sought out additional certifications in lipidology, nutrition, personal training, functional medicine, and behavioral change.
It is through this specialized training and working with thousands of patients I recognized how to provide better care. Your health is too important to trust to guidelines designed for the ‘average’ person. You are not average, nor should you want to be!
I also recognize the need for better access and convenience. That’s the heartbeat behind Concierge Preventive Cardiology: open access so together, we can evaluate every facet of who you are and how you can best achieve your goals.
I’m glad you’re here. It tells me you know you deserve better care. I can’t wait to get started finding your path to true health.
Bret Scher, MD FACC
Board Certified Cardiologist and Lipidologist
Yes, People LOVE Dr. Scher’s Approach

Don’t look now, but the updated clinical practice cholesterol guidelines from the American College of Cardiology, the American Heart Association and others are getting personal. Although the guidelines still contain their familiar approach — that I consider too aggressive with drug therapy — the latest 2018 version of the guidelines now includes an impressive update to emphasize lifestyle intervention, plus a more individualized approach for risk assessment.
MedPage Today: AHA: Revised Lipid Guide Boosts PCSK9s, Coronary Calcium Scans
Could this be the start of a progressive trend away from shotgun statin prescriptions? I sure hope so.
Prior guidelines emphasized the 10-year ASCVD risk calculator as the main determining factor for statin therapy. In the 2018 update, the guidelines acknowledge that the calculator frequently overestimates the risk in those individuals who are more involved with prevention and screening. (In other words, those patients more interested in and proactive about their health; I find many in the low-carb world fall into this category.)
The ensuing discussion with a healthcare provider should then focus on:
[T]he burden and severity of CVD risk factors, control of those other risk factors, the presence of risk-enhancing conditions, adherence to healthy lifestyle recommendations, the potential for ASCVD risk-reduction benefits from statins and antihypertensive drug therapy, and the potential for adverse effects and drug–drug interactions, as well as patient preferences regarding the use of medications for primary prevention… and the countervailing issues of the desire to avoid “medicalization” of preventable conditions and the burden or disutility of taking daily (or more frequent) medications.
I appreciate the attention the new guidelines bring to the depth of the discussion that should ensue between doctor and patient. Considering the treatment burden is equally as important as the burden of disease, and possibly even more important in patients who have not been diagnosed with heart disease, these individualized discussions about trade-offs are critical to personalized care.
Also worthy of mention is the increased use of coronary artery calcium scores (CAC) to help individualize risk stratification. The updated guidelines specify CAC may be useful for those age 40-75 with an intermediate 10-year calculated risk of 7.5%-20%, who after discussion with their physician are unsure about statin therapy. They specify that a CAC of zero would suggest a much lower risk than that calculated by the ASCVD risk formula, and thus take statins off the table as a beneficial treatment option.
This is huge. I cheered when I read this! I have been critical of prior guidelines that focused on ways to find more people to place on statins. The mention of finding individuals unlikely to benefit from statins is a giant step in the right direction.
The guidelines go even further: they mention that a CAC either over 100 or greater than the 75th percentile for age increases the CVD risk and the likely benefit of a statin. A CAC between 1-99 and less than the 75th percentile does not affect the risk calculation much and it may be worth following the CAC in five years in the absence of drug therapy. I would still argue that a CAC >100 does not automatically equal a statin prescription and we need to interpret it in context, but I greatly appreciate this attempt at a more personalized approach.
The guidelines also go beyond the limited risk factors included in the ASCVD calculator by introducing “risk modifying factors” such as:
- Premature family history of CVD
- Metabolic syndrome
- Chronic kidney disease
- Chronic inflammatory conditions such as rheumatoid arthritis and psoriasis
- Elevated CRP > 2.0 mg/L
- Elevated Lp(a) > 50 mg/dL or 125 nmol/L
- Elevated triglycerides > 175 mg/dL
Although they use these criteria to define an increased risk, the opposite would likely hold true. An absence of those criteria could define a lower risk situation.
Some changes deserve mention from a controversy standpoint as well. For instance, the new guidelines recommend checking lipid levels as early as two years old in some circumstances. Two!
They also recommend statin therapy for just about everyone with diabetes with no mention of attempting to reverse diabetes before starting a statin, a drug that has been shown to worsen diabetes and insulin resistance. In addition, the new guidelines do not mention the likely discordance between LDL-C and LDL-P in those with diabetes.
Last, the new guidelines define an LDL-C > 190 mg/dL as an absolute indication for statin therapy with a treatment goal of 190 mg/dL is in familial hypercholesterolemia populations (and even then has heterogenous outcomes). There is a clear lack of data supporting that same recommendation for metabolically healthy individuals with no other cardiac risk factors and no other characteristics of familial hypercholesterolemia. This is a clear example of when a guideline turns from “evidence based” to “opinion based.”
In summary, the guideline committee deserves recognition for its emphasis on an individualized care approach, its use of CAC, and its broader description of discussing potential drawbacks of drug treatment. It still combines opinion with evidence and believes all elevated LDL is concerning, but I for one hope it will continue its progression away from generalizations and someday soon see that individual risk variations exist, even at elevated LDL-C levels.
Thanks for reading,
Bret Scher MD FACC
Originally Posted on the Diet Doctor Blog

Can you find a more polarizing topic than statins? One article says they are miracle drugs that should be given to everyone. Then you turn the page, and you read how they are poison and you should stay away from them no matter what. How can one drug cause such differing views? And which should you believe?
The statin debate has intensified ever since the 2013 ACC/AHA cholesterol treatment guidelines increased the number of people without heart disease who “should” take a statin to 43 million Americans. That is for primary prevention, meaning the individual has never had a diagnosis of cardiovascular disease, never had a heart attack, and never had any type of a heart problem.
As you can imagine, this has been a windfall for the drug companies. But are we healthier and better off as a result? That is unknown.
The problem is understanding the bias of whoever is writing the story.
Subtleties of Science
But wait, you say. Won’t the science tell us if statins are good or not? Isn’t it an objective fact if they are good for us?
Not so fast. Beauty is in the eye of the beholder, and so is the application of science.
Are you getting advice from someone who believes prescribing more medicine is better? Or someone who believes a more natural lifestyle is better?
Are you reading a report sponsored by the pharmaceutical company that paid for the research?
Or are you getting advice from a scientist who is more focused on statistical benefits, or someone who is more concerned with the potential benefit for the one individual they are taking care of at the moment?
It is a confusing sea of conflicting information, and you have to find which approach resonates more with your beliefs and your life.
The Three Keys
Regardless of who you are and your beliefs, I promised you the three most important things you need to know about statins. Here they are:
- All statin studies are worthless! That’s right. All statin studies that have been done to date are worthless and don’t apply to anyone who follows healthy lifestyle principles.
- Statins will not prolong your life. Not at all. Not for a single day.
- Statins DO reduce your heart attack risk, by about 0.7% over 5 years.
All of a sudden, statins don’t seem so powerful, do they? Let’s go deeper into these points to learn why.
1-All Statin Trials Are Worthless
When designing a trial, you have to decide what your control group is going to be. You have to show that the drug is better than something. The key is defining what that something is.
Therein lies the problem. In order to show beneficial effects, primary prevention statin trials need thousands of subjects, studied over years. That is very expensive to do. The vast majority of trials, therefore, rely on drug company funding.
Do you think they are going to fund a trial that makes it easier or harder to show a benefit? Of course, that was a rhetorical question.
Pharma companies don’t have an interest in your health and wellbeing. Their priority is to their stock holders and their bottom line. They are going to sponsor trials that are most likely going to benefit them.
How does this make the trials worthless? They compare statins to “usual care.” That means a brief, and ineffective attempt to educate people about healthy nutrition and physical activity.
In addition, the specific nutritional guidance that was used has always been a low-fat diet. As we now know, what does a low-fat diet usually include? Lots of sugars and simple carbohydrates. What does that diet do? Increase your risk of obesity, diabetes, inflammation, and eventually heart disease.
That’s setting the bar pretty low to show a benefit from statins. And that is exactly what the drug companies want.
What we need is a control group that is involved in a comprehensive lifestyle intervention program. A program that helps participants get regular physical activity. Helps them eat vegetable based, real food, low in added sugars and simple carbs, and high in natural healthy fats.
Since that is the way we should all be living, THAT is what the control group should be. I guarantee you, the results would be far different compared to the standard control groups used to date.
That is the trial the drug companies never want to see and will never fund. And that is why all statin trials to date are worthless.
If you can focus on proper lifestyle interventions, using healthy foods, physical activity and stress management as medicine, then we have no idea what effect, if any, statins would have. But I assure you it will be minimal if any benefit.
2-Statins Will Not Prolong Your life
You read that right. For people who have never had heart disease before, the multi-billion dollar drug won’t help you live longer. The overwhelming majority of primary prevention trials involving statins show no difference in overall mortality between those who took the drug and those who did not.
That surprises a lot of people. Statins are promoted as if they are wonder drugs that save lives left and right. That’s good marketing and good PR. Reality is far different.
If they don’t help you live longer, they must increase the quality of your life, right? Nope. In fact, 30-40% of people on statins will experience muscle aches and weakness causing them to exercise less and decreasing the overall quality of their lives.
So, if they don’t help us live longer, and they don’t increase the quality of our lives, why do we take them????
3-Statins DO Reduce Your Heart Attack Risk
If the news was all bad there wouldn’t be any debate about their use. But the truth is that statins do reduce the risk of heart attacks, and that is why in some cases it may be beneficial for you to take one.
But the big question is: How much do statins reduce your heart attack risk? The answer is not as much as you would think. Considering the recommendations keep getting more and more aggressive for statin therapy, you would think statins would be immensely powerful at reducing heart disease risk.
In reality, they reduce the risk of a heart attack by 0.7-1.5% over 5 years. That means you need to treat 66-140 people for 5 years to prevent one heart attack. (as an aside, for people with pre-existing heart disease, so called secondary prevention, you need to treat approximately 40 people for 5 years to prevent 1 heart attack and 85 people to prevent 1 death)
When presented like that, it should certainly temper the enthusiasm for statin therapy. Again, it may still be the right choice for some people, but given the potential risks and side effects, I would hope for a much greater benefit.
Better Than Statins
A common response is that statins are “the best we have to offer” to reduce one’s risk of cardiovascular disease. If you are talking about a drug manufactured in a laboratory, then that would be correct. But what else are options?
It turns out following a Mediterranean eating pattern with vegetables, fruit, fish, legumes, and lots of nuts, olive oil and avocados reduces the risk of cardiovascular events as well. For something as simple as nutritional choices the benefit must be much less than a statin, right?
That is what the drug companies would want you to believe. In reality, you need to “treat” 61 people with the Mediterranean diet for 5 years to reduce 1 cardiovascular event (a “combined endpoint” of stroke, heart attack or death).
To be fair, you cannot compare one trial to another as they have very different populations studied, and the outcome measures are different. So, it is not scientifically fair to say, “The Mediterranean diet has been proven to be more beneficial that statins.” That would require a head-to-head trial. Unfortunately, that trial is unlikely to ever happen.
But it makes for an obvious answer when asked “If statins aren’t all that helpful, what else can I do to reduce my risk of cardiovascular disease?
- Follow a real food, vegetable-based, Mediterranean style diet, low in sugar and high in healthy fats.
- Maintain a physically active lifestyle.
- Exercise with some form of moderate cardio exercise, resistance training and higher intensity interval exercises.
- Practice stress reduction techniques.
- Don’t smoke.
- Manage your other risk factors such as diabetes and high blood pressure.
If you can follow these healthy lifestyle principles, you will be doing far more for your health than any pill you could take. And the best part? The only side effects are having more energy, feeling more empowered, and reducing your risk for chronic diseases. Sounds like a good trade off to me!
Thanks for reading.
Bret Scher, MD FACC
Cardiologist, author, founder of Boundless Health
www.DrBretScher.com

What do I mean by “misunderstood?” Look no further than the common misnomer of “good” or “bad” cholesterol.
Good and Bad Cholesterol
While it may be true that High-Density Lipoprotein (HDL) has potentially beneficial functions (reverse cholesterol transport), we have to remember there is no such thing as good and bad cholesterol. The cholesterol carried by HDL is the same as that carried by LDL. The only thing that makes it good or bad is if it ends up synthesizing our hormones or bile acids (good), or if it ends up in our vessel walls (bad).
If it’s true there is no such thing as good and bad cholesterol, why do we care about our HDL levels?
First, let’s start with the basics.
HDL is the smallest and most densely packed lipoprotein and has one or more ApoA protein on its surface. HDL can help lipids move around in circulation by accepting triglycerides or cholesterol from other particles, thus helping a VLDL turn into an LDL, or helping an LDL contain less cholesterol (turning a small dense LDL into a less densely packed LDL).
Like LDL, HDL transports cholesterol to the liver for recycling or excretion, or to the hormone producing cells like in the adrenals. Unlike LDL, HDL does not have the potential to get retained in the vascular wall and does not, therefore, contribute to plaque formation. In fact, functioning HDL can remove cholesterol from the vessel wall, thus putting it back into circulation and possibly removing it from the body.
Back to the question at hand.
Why should we care about HDL levels?
Early epidemiological trials showed that lower HDL levels were associated with a higher risk of cardiovascular disease and even death. With such a strong association, the medical profession promoted elevated HDL levels as protective and low levels as something we need to avoid.
Since these were observational epidemiological studies, they do not prove that the low HDL caused the problems, only that HDL was associated with it. For instance, HDL is also known to be low in diabetes, metabolic syndrome and insulin resistance. It may, therefore, simply be a marker of underlying metabolic dysfunction that contributes to increased risk. Yet, HDL’s function in reverse cholesterol transport, and its ability to remove cholesterol from vessel walls suggests a more direct impact on cardiovascular health.
It is also important to note that the Framingham data suggested that increased cardiovascular risk with elevated total cholesterol and LDL-C was lost in the presence of high HDL. In fact, very low levels of LDL combined with very low HDL levels had a much higher risk than markedly elevated LDL levels when combined with elevated HDL.
Thus, HDL proves to be a useful marker to help predict cardiovascular risk. For instance, one large meta-analysis showed that total cholesterol/HDL ratio was a much stronger predictor of cardiac mortality than total cholesterol alone.
In addition, the PURE study, an observational trial in over 135,000 subjects, showed that when considering lipid changes brought about by nutritional changes, ApoB/ApoA1 (essentially LDL-P/HDL-P ratio) is the best predictor of clinical outcomes.
Thus, HDL level is important in assessing cardiovascular risk.
Drugs Muddy the Picture
While HDL may be a good predictor of risk, raising it with drugs does not seem to confer added benefit.
For instance, cholesterol ester transferase protein inhibitors (CETP inhibitors) significantly reduced LDL by 20-30% and increased HDL 100-fold, yet showed either no clinical benefit or even worse, an increased risk of death.
This was a shock to many in the lipid world as the notion of “good” and “bad” cholesterol would clearly predict lowering LDL and raising HDL would confer dramatic health benefits. So much so, that multiple pharmaceutical companies invested hundreds of millions of dollars developing these drugs only to abandon them when the trials showed no benefit.
Part of the issue is that not all HDL lipoproteins function the same. There are subsets of people with genetically determined markedly elevated HDL levels who have an increased risk of CVD. They may have plenty of cholesterol circulating in HDL particles, but the HDL particles are dysfunctional and therefore do not effectively remove cholesterol from vessel walls or LDL and do not effectively transport it to the liver. Conversely, there are those with a specific genetic mutation called ApoA1 Milano who have very low HDL-C and lower cardiovascular risk.
Simply measuring the HDL cholesterol content, therefore, may not accurately reflect its function. While we do not have easily available tests to measure HDL function, we can potentially use HDL particle assessment as well as the company it keeps (i.e. low triglycerides, larger less dense LDL particles) to better assess the potential benefits of HDL. Thus, if there is any concern about potentially dysfunctional HDL, I usually recommend advanced lipid testing to see the specific subtypes of HDL.
What can we conclude from all the HDL confusion?
Raising HDL with drugs does not reduce cardiovascular events, yet having a naturally low HDL is associated with increased risk.
The best answer, therefore, is to live a lifestyle that helps you have a “not low” HDL level. This means first and foremost avoiding the medical conditions associated with low HDL (i.e. insulin resistance, diabetes, and metabolic syndrome).
Textbooks predictably state the interventions to naturally raise HDL include exercise and moderate alcohol intake. Unfortunately, these have minimal effects. In fact, they pale in comparison to a low carb high fat lifestyle. In my 20+ years in the medical field, I have never seen an intervention as effective as LCHF in raising HDL, and the studies agree.
This brings us back to our question once again.
Why are HDL levels important?
HDL levels are important because it is a reflection of our underlying metabolic health and our lifestyle. A properly constructed LCHF lifestyle lowers triglycerides, raises HDL, and reduces the small dense LDL, among other benefits. Such a lifestyle likely reduces overall cardiovascular risk and will likely be shown to improve longevity and health span. While HDL may not be the main reason for this, we can’t ignore its role simply because it is more nuanced than “good” and “bad” cholesterol.
My advice, therefore, is to see the whole picture. Embrace the nuance. And make sure you get a thorough and proper evaluation of your cardiovascular risk.
If you are hungry for more, I created my Truth About Lipids program, a program focused on Cholesterol, to help break through the confusion and provide you with everything you need to thoroughly understand cholesterol and its impact on your health.
Learn more: Truth About Lipids Program
If you still have questions, you may want to consider a one-on-one health coaching consultation so you can get the individual attention you deserve with a thorough assessment of your lifestyle and its impact on you as an individual.
Please comment below if you have any questions or comments that may help further the discussion.
Thanks for reading.
Bret Scher MD FACC

Do we have to avoid meat if we have high homocysteine levels? Not really.
What our body does with homocysteine is more important than our food intake. I thought this was easier to explain in video form, so you can see my 4 minute explanation here:
The bottom line is we need to know our methylation status, make sure we have adequate levels of folate, B12 and B6, and make sure we have adequate choline (found in egg yolks). If all those are perfect, and we still have elevated homocysteine, then we may want to experiment with a diet low in methionine to see if it makes a difference.
As always, however, we have to evaluate our overall health picture and not get too hung up on one blood marker. The more important questions to ask are how does homocysteine affect my overall health, and how will altering my supplements or diet change the big picture?
Hopefully this helps! Let me know if you have any comments or questions.
Thanks for reading (and watching!)
Bret Scher MD FACC

We hear the words Heart Healthy a lot, especially when it comes to our nutrition.
By now, you’re likely used to seeing cereals with the “heart healthy” moniker. Is it really heart healthy? We all too frequently refer to foods as “heart healthy”, or we say that our doctor gave our hearts a “healthy” checkup.
It all sounds nice. But what does it mean? How do we define heart health?
How does LDL Cholesterol affect Heart Health?
Unfortunately, most of our current definitions center around LDL cholesterol concentration. While LDL cholesterol plays a role in heart health, it by no means defines heart health in totality.
In fact, in many cases it is the least important factor.
Our healthcare system has simplified things too much, so as a result we focus on one bad guy, one demon to fight. In reality heart disease is caused, and made more likely to occur, by a constellation of contributing issues.
Elevated blood sugar, elevated insulin levels, inflammation, high blood pressure, poor nutrition, and yes, lipids all contribute to heart health. It does us all an injustice to over simplify it to one single cause.
What food is heart healthy?
Our superficial definition of cardiac risk is how industrial seed oils containing polyunsaturated fatty acids (PUFAs) became known as “heart healthy.”
Studies show that they can lower LDL. But they can also increase inflammation and have no clinical benefit and even increase risk of dying. According to our simplified definitions, that doesn’t stop them from being defined as “heart healthy.”
That’s right! Something that increases our risk of dying is still termed “heart healthy.” How’s that for a backwards medical system?!
Same for blood sugar. If you have a diagnosis of Type 2 Diabetes (DM2) that is a risk for cardiovascular disease. If you don’t have the diagnosis, you are fine. That ignores the disease of insulin resistance that can predate diabetes for decades and increases the risk of heart disease and possibly even cancer and dementia.
Cereal can also be called “heart healthy” as they may minimally lower LDL. But is that a good thing if they contain grains that also worsen your insulin resistance and metabolic syndrome? I say definitely not.
Time has come to stop this basic, simplified evaluation and start looking at the whole picture.
How Low Carb High Fat Diets Improve Heart Health
Low carb high fat diets have been vilified as they can increase LDL. But the fact of the matter is that it does so only in a minority of people. The truth is that they can improve everything else!
These diets reduce blood pressure, reduce inflammation, improve HDL and triglycerides, and reverse diabetes and metabolic syndrome! Shouldn’t that be the definition of “heart healthy” we seek? Instead of focusing on one isolated marker, shouldn’t we define heart health by looking at the whole patient?
Only by opening our eyes and seeing the whole picture of heart healthy lifestyles can we truly make an impact on our cardiovascular risk and achieve the health we deserve.
Join me in demanding more. Demand better.
Thanks for reading,
Bret Scher, MD FACC
TAKING YOUR NEXT STEP
WITH BOUNDLESS HEALTH AND DR. SCHER
We are excited to help you in your quest for better health! If you are ready to take the next step, your annual membership will give you access to:
START A CONVERSATION
Connect with Dr. Scher to see if this model is right for you today.
Let’s Talk
Send us a message and let us know how we can help you.
